C4 Therapeutics, Inc. (CCCC) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$98.69M | -51.5% |
| 2024 | -$65.16M | +39.0% |
| 2023 | -$106.84M | -0.8% |
| 2022 | -$105.94M | -21.8% |
| 2021 | -$86.97M | -29.3% |
| 2020 | -$67.25M | -220.9% |
| 2019 | $55.61M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$98.69M | -51.5% |
| 2024 | -$65.16M | +39.0% |
| 2023 | -$106.84M | -0.8% |
| 2022 | -$105.94M | -21.8% |
| 2021 | -$86.97M | -29.3% |
| 2020 | -$67.25M | -220.9% |
| 2019 | $55.61M | — |